AR-Aid Patient Management Tool
In the clinical trial,
OTHER ARs REPORTED IN ≥10% (ANY GRADE) OR ≥3% (GRADES 3-5) OF PATIENTS WITH R/R AML
Body Systems AR |
All grades N=214 (%) |
≥Grade 3 N=214 (%) |
---|---|---|
Gastrointestinal disordersa |
||
Nausea |
107 (50) |
11 (5) |
Diarrhea |
91 (43) |
17 (8) |
Vomiting |
73 (34) |
4 (2) |
Metabolism and nutrition disorders |
||
Decreased appetite |
73 (34) |
9 (4) |
Tumor lysis syndrome (TLS)b |
13 (6) |
12 (6) |
Nervous system disorders |
||
Dysgeusia |
25 (12) |
0 (0) |
aGastrointestinal disorders observed with IDHIFA® treatment can be associated with other commonly reported events, such as abdominal pain and weight decrease.
bTLS observed with IDHIFA® treatment can be associated with commonly reported uric acid increase.
ADDITIONAL ANALYSIS: FREQUENCY OF ADVERSE REACTIONS OVER TIME1
In addition to the ARs reported above, blood and lymphatic system disorders have been reported, including differentiation syndrome and noninfectious leukocytosis.
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
Other Grade 3* or higher toxicity considered related to treatment including tumor lysis syndrome
*Grade 1 is mild, Grade 2 is moderate, Grade 3 is serious, and Grade 4 is life-threatening.
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
Eligibility
Patients must meet the following criteria to enroll:
Program Benefits
Program Timing
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216
This site is intended for U.S. audiences only.